Protagonist Therapeutics, Inc. (PTGX) stock analysis

In our weekly check, Protagonist Therapeutics, Inc. is graded C (A to F). Of 22 checks on debt, profit, cash flow and trend: 12 pass, warnings: 5, red flags: 5.

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as PTGX.

What our checks show for PTGX

Red flags

Warning signs

Strengths

Similar companies

KRYS · RYTM · PRAX · CYTK · ABVX · TGTX

Questions

What grade does Protagonist Therapeutics, Inc. (PTGX) have?

In our weekly check, Protagonist Therapeutics, Inc. is graded C (A to F). Of 22 checks on debt, profit, cash flow and trend: 12 pass, warnings: 5, red flags: 5. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of PTGX stock?

This week's biggest flags for Protagonist Therapeutics, Inc.: Profits not backed by cash, Weak revenue forecast, Margins expected to shrink. In total 10 of 22 checks show a warning or a red flag.

What does Protagonist Therapeutics, Inc. do?

Protagonist Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as PTGX.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-11-14

Open the full analysis